Renalytix Q3 2024 GAAP EPS $(0.08) Misses $(0.07) Estimate, Sales $535.000 Miss $950.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Renalytix reported its Q3 2024 financial results, with a GAAP EPS of $(0.08), missing the $(0.07) estimate. Sales were $535,000, falling short of the $950,000 estimate.
May 15, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Renalytix reported a GAAP EPS of $(0.08) for Q3 2024, missing the $(0.07) estimate. Sales were $535,000, significantly below the $950,000 estimate. This underperformance may negatively impact the stock price in the short term.
The company's earnings and sales both missed estimates, which is likely to result in a negative market reaction. Investors often react unfavorably to such earnings misses, leading to a potential decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100